anti-CD66b (human), mAb (ANC1D5) (preservative free)
| Code | Size | Price |
|---|
| ANC-217-820-100ug | 100 ug | £243.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: Mouse IgG1kappa
Antibody Clonality: Monoclonal
Antibody Clone: ANC1D5
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Fluorescence-activated cell sorting (FACS)
Shipping:
BI
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
CEACAM8; Carcinoembryonic Antigen-related Cell Adhesion Molecule 8
Concentration:
1mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
50mM Sodium Phosphate pH 7.5, 100mM Potassium Chloride, 150mM NaCl.
Handling Advice:
Avoid freeze/thaw cycles.Keep sterile.
Immunogen:
Recombinant soluble human CD66b.
Labels - Conjugates:
Preservative Free
Long Description:
Monoclonal Antibody. Binds to CD66b on the cell surface of human PMN in flow cytometry and detects recombinant human CD66b in sandwich EIA utilizing either clone ANC4A4(Cat #ANC-220-020) or ANC3C5(Cat# ANC-219-020) as a capture reagent. May cross-react with other CD66 isoforms, as it also binds to the cell surface of an epithelial tumor line. Applications: ELISA, FACS. Isotype: Mouse IgG1kappa. Clone: ANC1D5. Liquid. 50mM Sodium Phosphate pH 7.5, 100mM Potassium Chloride, 150mM NaCl. Human CD66b (CEACAM8, CGMb, NCA-95, CD67) is a 95kD member of the Carcinoembryonic Antigen (CEA) group. It is expressed on granulocytes and functions as an adhesion molecule. Similar to the CD66 a, c, and d isoforms, engagement of CD66b on neutrophils causes increased adhesion to endothelial cells. Crosslinking CD66b on neutrophils with antibodies triggers IL-8 release.
NCBI, Uniprot Number:
P31997
Package Type:
Plastic Vial
Product Description:
Human CD66b (CEACAM8, CGMb, NCA-95, CD67) is a 95kD member of the Carcinoembryonic Antigen (CEA) group. It is expressed on granulocytes and functions as an adhesion molecule. Similar to the CD66 a, c, and d isoforms, engagement of CD66b on neutrophils causes increased adhesion to endothelial cells. Crosslinking CD66b on neutrophils with antibodies triggers IL-8 release.
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Binds to CD66b on the cell surface of human PMN in flow cytometry and detects recombinant human CD66b in sandwich EIA utilizing either clone ANC4A4(Cat #ANC-220-020) or ANC3C5(Cat# ANC-219-020) as a capture reagent. May cross-react with other CD66 isoforms, as it also binds to the cell surface of an epithelial tumor line.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
Related Products
| Product Name | Product Code | Supplier | anti-CD66b (human), mAb (ANC1D5) | ANC-217-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-CD66b (human), mAb (ANC1D5) (Biotin) | ANC-217-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC1D5) (FITC) | ANC-217-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC3C5) | ANC-219-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC3C5) (Biotin) | ANC-219-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC3C5) (FITC) | ANC-219-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC4A4) | ANC-220-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC4A4) (Biotin) | ANC-220-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD66b (human), mAb (ANC4A4) (FITC) | ANC-220-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||